Artificial gene synthesis

GenScript to Host Third Annual Gene & Cell Engineering Virtual Summit

Retrieved on: 
Thursday, July 20, 2023

PISCATAWAY, N.J., July 20, 2023 /PRNewswire/ -- GenScript USA Inc., the world's leading life-science research tools and services provider, announced its third annual GenScript Gene & Cell Engineering Virtual Summit, which will feature in-depth discussions and research presentations on the crucial gene-synthesis and cell-editing technologies that are transforming scientific and biomedical research today. 

Key Points: 
  • This free Summit will be held on July 26, 2023, from 11 a.m. to 6 p.m. EDT.
  • "As a leader in gene synthesis and gene editing technologies, GenScript has been fortunate to work with many pioneering scientists in cell and gene engineering," said Ray Chen, Ph.D., president of GenScript Life Science Group.
  • The summit showcases the role of genetic engineering in revolutionizing life-science research, advancing gene and cell therapies, and enabling the efficient development of invaluable biotherapeutics for various human diseases.
  • Dr. Yongli Shan, associate director of discovery biology at Vicinitas Therapeutics — Advancing protein stabilization therapeutic development and DUBTAC drug discovery through gene and cell engineering.

GenScript Expands Footprint in Singapore to Provide Premium Gene Synthesis Service

Retrieved on: 
Tuesday, February 28, 2023

SINGAPORE, Feb. 28, 2023 /PRNewswire/ -- GenScript Biotech Corporation, the world's leading provider of life-science research tools and services, announced the expansion of its Singapore facility to provide a premium gene synthesis service. The move adds an additional 976 square meters to the facility, bringing the total production footprint in Singapore to 3,500 square meters, and making it the third-largest GenScript facility worldwide. The expansion will also increase the total headcount at the Singapore facility to 150.

Key Points: 
  • The move adds an additional 976 square meters to the facility, bringing the total production footprint in Singapore to 3,500 square meters, and making it the third-largest GenScript facility worldwide.
  • In February 2022, GenScript Asia-Pacific announced the opening of new recombinant protein production facility; now, that same facility will offer an advanced gene-synthesis service.
  • This marks a significant expansion of the company's advanced gene-synthesis capability and enables GenScript to provide the premium service levels required for novel vaccine and therapeutics development in life sciences.
  • "The expansion of our cutting-edge facility in Singapore boosts GenScript's gene synthesis production capabilities, enabling us to meet the exacting demands of our regional biotech clients," said Johnson Wang, president of GenScript Asia-Pacific.

GenScript to Host 2nd Annual Gene & Cell Engineering Virtual Summit

Retrieved on: 
Tuesday, July 26, 2022

PISCATAWAY, N.J., July 26, 2022 /PRNewswire/ -- GenScript USA Inc., the world's leading life-science research tools and services provider, announced its second annual GenScript Gene & Cell Engineering Virtual Summit, which will feature in-depth discussions and research presentations on the crucial gene-synthesis and cell-editing technologies that are transforming scientific and biomedical research today.

Key Points: 
  • This free Summit will be held on July 28, 2022, from 11 a.m. to 6 p.m. EDT.
  • "As a leader in gene synthesis and gene editing technologies, GenScript has been fortunate to work with many of the pioneering scientists in cell and gene engineering," said Ray Chen, Ph.D, president of GenScript Life Science Group.
  • This year's summit features scientists from Cleveland Clinic, Genentech, Indee Labs, Legend Biotech, Neogene, Stanford University, TScan Therapeutics, and Yale University.
  • The summit showcases the role of synthetic biology in revolutionizing life-science research, advancing gene and cell therapies, and enabling the efficient development of invaluable biotherapeutics for various human diseases.

Synthetic Biology Markets, 2026: Tissue Regeneration, Biofuel, Consumer Care, Food & Agriculture, Environmental - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 8, 2021

Factors such as the increasing demand for synthetic genes and synthetic cells, wide range of applications of synthetic biology, declining cost of DNA sequencing and synthesizing, increasing R&D funding and initiatives in synthetic biology, and increasing investments in the market are propelling the growth of this market.

Key Points: 
  • Factors such as the increasing demand for synthetic genes and synthetic cells, wide range of applications of synthetic biology, declining cost of DNA sequencing and synthesizing, increasing R&D funding and initiatives in synthetic biology, and increasing investments in the market are propelling the growth of this market.
  • However, rising biosafety, biosecurity, and ethical concerns related to synthetic biology is likely to hamper the growth of this market.
  • On the basis of tool, the synthetic biology market is broadly segmented into oligonucleotides & synthetic DNA, enzymes, cloning technology kits, synthetic cells, chassis organisms, and xeno-nucleic acids.
  • Based on application, the synthetic biology market is segmented into medical applications, industrial applications, food & agriculture, and environmental applications.

Oligonucleotide Synthesis Markets, 2026 by Product (Drug, Synthesized Oligos (Primer, Probe), Reagents), Type (Custom, Predesign), Application (Therapeutic (ASO, siRNA), Research (PCR), Diagnostic) - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 19, 2021

By product, the synthesized oligonucleotides market is segmented into primers, probes, DNA oligos, RNA oligos, and other synthesized oligos such as BNA & LNA oligos.

Key Points: 
  • By product, the synthesized oligonucleotides market is segmented into primers, probes, DNA oligos, RNA oligos, and other synthesized oligos such as BNA & LNA oligos.
  • In 2020, the primers segment accounted for the fastest growing segment of this market, as they are used in various applications such as PCR, sequencing, gene synthesis, and cloning applications, among others.\nBased on application, the oligonucleotide synthesis market is segmented into therapeutic, research, and diagnostic applications.
  • The therapeutic application segment is further segmented into Antisense oligonucleotide-based therapies, siRNAi oligonucleotide-based therapies, and CpG oligonucleotide-based therapies.
  • Factors such as growing R&D funding, rising product availability, lower outsourcing costs, increasing research activities, increasing applications of oligos in molecular diagnostics & therapeutics, and the rising awareness of oligonucleotides are expected to drive market growth.\nNorth America accounted for the largest market share.

Codex DNA Releases Long Gene Fragment Cloning On The BioXp™ System

Retrieved on: 
Tuesday, May 4, 2021

b'San Diego, CA, May 04, 2021 (GLOBE NEWSWIRE) -- Codex DNA, Inc., creators of the BioXp\xe2\x84\xa2 system, a fully automated benchtop instrument that enables\xc2\xa0numerous\xc2\xa0synthetic biology workflows, announced the addition of longer fragment cloning to the BioXp\xe2\x84\xa2 system.

Key Points: 
  • b'San Diego, CA, May 04, 2021 (GLOBE NEWSWIRE) -- Codex DNA, Inc., creators of the BioXp\xe2\x84\xa2 system, a fully automated benchtop instrument that enables\xc2\xa0numerous\xc2\xa0synthetic biology workflows, announced the addition of longer fragment cloning to the BioXp\xe2\x84\xa2 system.
  • Scientists are now able to produce error-corrected, multivariant, de novo synthetic genes up to 7.2 kilobase pairs (kb) in length, and clone them into custom vectors hands-free and overnight, using the company\xe2\x80\x99s Gibson Assembly\xc2\xae technology.\n\xe2\x80\x9cWe\xe2\x80\x99ve developed a process for automated synthesis of long gene fragment cloning using the BioXp\xe2\x84\xa2 system.
  • This enables our customers to create error-corrected genes at a faster rate while eliminating the need to synthesize them manually or through outsourcing,\xe2\x80\x9d said Todd R. Nelson, PhD, Chief Executive Officer of Codex DNA.
  • Codex DNA is accelerating advances in the fields of personalized medicine, antibody engineering, vaccine development, drug discovery, and DNA storage.\n'

Twist Bioscience Expands Gene Product Line with Launch of Clonal-Ready Gene Fragments

Retrieved on: 
Thursday, December 10, 2020

Twists best-in-class Gene Fragments, with and without adapters, can be used to build constructs and minimize the time and cost of screening for perfect clones.

Key Points: 
  • Twists best-in-class Gene Fragments, with and without adapters, can be used to build constructs and minimize the time and cost of screening for perfect clones.
  • Gene Fragments begin as oligonucleotides synthesized on Twist Biosciences proven semiconductor-based silicon platform.
  • The resulting product is a ready-to-use Gene Fragment that is compatible with many applications including cloning, gene and protein expression, pathway and enzyme engineering and enzyme optimization.
  • Based on a comparative study conducted by Twist, Twist Gene Fragments demonstrated the lowest error rate, with a nearly 2-fold improvement across all Gene Fragment size ranges at 1:5,300.

Gene Synthesis - Global Market Review 2014-2018 and Forecast 2019-2029 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 17, 2020

Global Gene Synthesis Market Demand (Size in US$ Mn) Analysis 2014-2018 and Forecast, 2019-2029

Key Points: 
  • Global Gene Synthesis Market Demand (Size in US$ Mn) Analysis 2014-2018 and Forecast, 2019-2029
    5.1.
  • Global Gene Synthesis Market Analysis 2014-2018 and Forecast 2019-2029, by Service
    7.2.
  • Global Gene Synthesis Market Analysis 2014-2018 and Forecast 2019-2029, by Application
    8.2.
  • Global Gene Synthesis Market Analysis 2014-2018 and Forecast 2019-2029, by End User
    9.2.

Twist Bioscience Expands Flexibility of Clonal Genes for Pharmaceutical, Biotechnology and Industrial Chemical Research

Retrieved on: 
Monday, April 20, 2020

Twist Bioscience Corporation (Nasdaq: TWST) today announced the enhanced Twist Clonal Genes product line with the expansion of preparation quantities, delivery formats, buffer options, and tube and plate options.

Key Points: 
  • Twist Bioscience Corporation (Nasdaq: TWST) today announced the enhanced Twist Clonal Genes product line with the expansion of preparation quantities, delivery formats, buffer options, and tube and plate options.
  • Clonal genes are full-length genes cloned into a plasmid, a molecule that can replicate independent of standard genetic replication in the chromosomes.
  • Clonal genes can be used in a wide range of studies including multiple areas of the drug discovery and development process.
  • Twist Bioscience is transforming gene synthesis, which is a process at the core of synthetic and molecular biology.

Brooks to Participate in the 19th Annual Needham Virtual Healthcare Conference

Retrieved on: 
Wednesday, April 8, 2020

CHELMSFORD, Mass., April 8, 2020 /PRNewswire/ --Brooks Automation, Inc. (Nasdaq: BRKS) announced today that company management will participate in the 19th Annual Needham Virtual Healthcare Conference on Tuesday, April 14, 2020 at 10:40 a.m.

Key Points: 
  • CHELMSFORD, Mass., April 8, 2020 /PRNewswire/ --Brooks Automation, Inc. (Nasdaq: BRKS) announced today that company management will participate in the 19th Annual Needham Virtual Healthcare Conference on Tuesday, April 14, 2020 at 10:40 a.m.
  • The 40-minute session will be webcast live via the Brooks investor relations website at www.brooks.investorroom.com/events .
  • Brooks (Nasdaq: BRKS) is a leading provider of life science sample-based solutions and semiconductor manufacturing solutions worldwide.
  • Brooks Life Sciences' GENEWIZ division is a leading provider of DNA gene sequencing and gene synthesis services.